Pharma major Dr Reddy’s Laboratories is expected to have faced continued pricing pressure in the US market, which could have weighed on its margins in the second quarter of the current financial year, ended September.
The Hyderabad-based company is scheduled to announce its Q2 FY27 results on October 23 (Friday).
Despite pricing pressure in the US and continued increases in logistics expenses driven by geopolitical factors affecting some markets, the drug maker is expected to report sequential improvements in revenue and profitability, though its EBITDA margin is likely to remain below 20 per cent.
Steady growth in the domestic market in recent quarters is also expected to support the company’s overall performance.
In Q2 FY26, the company had posted a consolidated net profit of ₹1,437 crore against revenues of ₹8,805 crore.
Published on October 22, 2026
